

Aitziber Buquã©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6079886/publications.pdf>

Version: 2024-02-01

59
papers

7,328
citations

186209

28
h-index

197736

49
g-index

61
all docs

61
docs citations

61
times ranked

11897
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Cytofluorometric assessment of cell cycle progression in irradiated cells. <i>Methods in Cell Biology</i> , 2022, , 1-16. | 0.5 | 2 |
| 2 | Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 440-462. | 21.5 | 58 |
| 3 | Nicotinamide drives T cell activation in the mammary tumor microenvironment. <i>Journal of Translational Medicine</i> , 2022, 20, . | 1.8 | 0 |
| 4 | Cytofluorometric assessment of acute cell death responses driven by radiation therapy. <i>Methods in Cell Biology</i> , 2022, , . | 0.5 | 0 |
| 5 | RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. <i>Methods in Cell Biology</i> , 2022, , . | 0.5 | 0 |
| 6 | Possible mechanisms of cancer prevention by nicotinamide. <i>British Journal of Pharmacology</i> , 2021, 178, 2034-2040. | 2.7 | 10 |
| 7 | Immunomodulation by targeted anticancer agents. <i>Cancer Cell</i> , 2021, 39, 310-345. | 7.7 | 131 |
| 8 | MPA/DMBA-driven mammary carcinomas. <i>Methods in Cell Biology</i> , 2021, 163, 1-19. | 0.5 | 5 |
| 9 | LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. <i>OncImmunology</i> , 2021, 10, 1962592. | 2.1 | 30 |
| 10 | Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1855-1863. | 3.2 | 41 |
| 11 | Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. <i>Methods in Cell Biology</i> , 2021, 163, xvii-xxv. | 0.5 | 0 |
| 12 | Ketosis versus carbotoxicity â€“ metabolism determines the outcome of cancer immunotherapy. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1868266. | 0.3 | 3 |
| 13 | Abstract PO-036: Immunological characterization of mouse HR+ mammary tumors relapsing after radiation therapy. , 2021, , . | | 0 |
| 14 | Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. <i>STAR Protocols</i> , 2021, 2, 100488. | 0.5 | 3 |
| 15 | Targeting Serine in Cancer: Is Two Better Than One?. <i>Trends in Cancer</i> , 2021, 7, 668-670. | 3.8 | 10 |
| 16 | Monitoring abscopal responses to radiation in mice. <i>Methods in Enzymology</i> , 2020, 635, 111-125. | 0.4 | 2 |
| 17 | Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741. | 12.5 | 701 |
| 18 | Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819. | 5.8 | 71 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. <i>Nature Immunology</i> , 2020, 21, 1160-1171. | 7.0 | 214 |
| 20 | NK cells beat T cells at early breast cancer control. <i>Oncolmunology</i> , 2020, 9, 1806010. | 2.1 | 8 |
| 21 | PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. <i>Oncolmunology</i> , 2020, 9, 1721810. | 2.1 | 79 |
| 22 | Methods to Detect Immunogenic Cell Death In Vivo. <i>Methods in Molecular Biology</i> , 2020, 2055, 433-452. | 0.4 | 5 |
| 23 | Apoptotic caspases cut down the immunogenicity of radiation. <i>Oncolmunology</i> , 2019, 8, e1655364. | 2.1 | 19 |
| 24 | Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. <i>Oncolmunology</i> , 2019, 8, e1655964. | 2.1 | 97 |
| 25 | Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. <i>Clinical Cancer Research</i> , 2019, 25, 6890-6892. | 3.2 | 0 |
| 26 | Anticancer effects of anti-CD47 immunotherapy <i>in vivo</i> . <i>Oncolmunology</i> , 2019, 8, 1550619. | 2.1 | 32 |
| 27 | Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolmunology</i> , 2018, 7, e1433982. | 2.1 | 38 |
| 28 | Modeling Tumor Immunology and Immunotherapy in Mice. <i>Trends in Cancer</i> , 2018, 4, 599-601. | 3.8 | 63 |
| 29 | Immunosuppressive cell death in cancer. <i>Nature Reviews Immunology</i> , 2017, 17, 402-402. | 10.6 | 13 |
| 30 | The complement system is also important in immunogenic cell death. <i>Nature Reviews Immunology</i> , 2017, 17, 143-143. | 10.6 | 6 |
| 31 | Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174. | 2.8 | 82 |
| 32 | Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , 2017, 17, 97-111. | 10.6 | 2,000 |
| 33 | Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160. | 7.7 | 410 |
| 34 | The ratio of CD8 ⁺ /FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i> . <i>Oncolmunology</i> , 2016, 5, e1218106. | 2.1 | 50 |
| 35 | Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmunology</i> , 2016, 5, e1214790. | 2.1 | 64 |
| 36 | Prevention of breast cancer by RANKL/RANK blockade. <i>Cell Research</i> , 2016, 26, 751-752. | 5.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1139275. | 2.1 | 21 |
| 38 | Trial Watchâ€”Immunostimulation with cytokines in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1115942. | 2.1 | 52 |
| 39 | Trial Watchâ€”Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740. | 2.1 | 88 |
| 40 | Trial Watchâ€”Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1149674. | 2.1 | 46 |
| 41 | Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1088631. | 2.1 | 104 |
| 42 | Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. <i>Journal of Cancer Therapy</i> , 2016, 07, 455-463. | 0.1 | 0 |
| 43 | Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. <i>Cancer Cell</i> , 2015, 28, 690-714. | 7.7 | 1,205 |
| 44 | Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411. | 2.1 | 97 |
| 45 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1008814. | 2.1 | 102 |
| 46 | eIF2Î± phosphorylation as a biomarker of immunogenic cell death. <i>Seminars in Cancer Biology</i> , 2015, 33, 86-92. | 4.3 | 95 |
| 47 | Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1046673. | 2.1 | 29 |
| 48 | Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. <i>Cancer Letters</i> , 2015, 368, 26-35. | 3.2 | 15 |
| 49 | Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531. | 2.1 | 26 |
| 50 | Morphometric analysis of immunoselection against hyperploid cancer cells. <i>Oncotarget</i> , 2015, 6, 41204-41215. | 0.8 | 13 |
| 51 | Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19036-e19036. | 0.8 | 0 |
| 52 | Estrogen Receptor 1 Gene Expression and Its Combination with Estrogen Receptor 2 or Aromatase Expression Predicts Survival in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e109659. | 1.1 | 20 |
| 53 | Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508. | 0.8 | 395 |
| 54 | Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691. | 2.1 | 686 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. <i>Clinical and Translational Oncology</i> , 2014, 16, 339-350. | 1.2 | 24 |
| 56 | Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells. <i>PLoS ONE</i> , 2013, 8, e63338. | 1.1 | 28 |
| 57 | Elderly patients and ovarian epithelial cancer (OEC) or primary peritoneal carcinoma (PPC): A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20718-e20718. | 0.8 | 0 |
| 58 | Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14712-e14712. | 0.8 | 0 |
| 59 | Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells. <i>Molecular Cancer</i> , 2012, 11, 25. | 7.9 | 30 |